Candel Therapeutics (CADL) Gains from Investment Securities (2020 - 2025)

Candel Therapeutics has disclosed Gains from Investment Securities across 6 years of filings, most recently posting $13.5 million for Q4 2025.

• Gains from Investment Securities for Q4 2025 came in at $13.5 million, up 131.81% year-over-year; the trailing twelve-month figure through Dec 2025 was $19.8 million (up 119.67% YoY), and the FY2025 annual result was $2.2 million, down 51.28% from the prior year.
• Gains from Investment Securities came in at $13.5 million for Q4 2025 at Candel Therapeutics, up from -$1.1 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $13.5 million in Q4 2025 to a low of -$2.7 million in Q4 2022.
• The 5-year median for Gains from Investment Securities is $1.6 million (2024), against an average of $2.8 million.
• Across the five-year window, Gains from Investment Securities slumped 274500.0% in 2022 and soared 23237.86% in 2025, its largest moves.
• Candel Therapeutics' Gains from Investment Securities stood at $1000.0 in 2021, then plunged by 274500.0% to -$2.7 million in 2022, then jumped by 157.22% to $1.6 million in 2023, then soared by 271.46% to $5.8 million in 2024, then jumped by 131.81% to $13.5 million in 2025.
• The last three Gains from Investment Securities figures came in at $13.5 million (Q4 2025), -$1.1 million (Q3 2025), and $6.1 million (Q2 2025), per Business Quant data.